Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Baird 2023 Global Healthcare Conference in New York City, NY, on Tuesday, September 12, 2023, at 4:55 p.m. ET. A webcast of the presentation will be available through the Investors and Media section of Geron's website under.

Geron to Participate in the Baird 2023 Global Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron's New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS). In addition, the FDA informed the.

Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron's New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS). “The FDA's acceptance of our New Drug Application is an important landmark.

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS

Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.07 per share a year ago.

Geron (GERN) Reports Q2 Loss, Lags Revenue Estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the second quarter of 2023. “We progressed our business significantly this quarter, as we evolve into a commercial company. Most notably, we submitted the first New Drug Application to the FDA for a telomerase inhibitor,.

Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its second quarter 2023 financial results on Thursday, August 3, 2023 at 4:00 p.m. Eastern Time via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results, as well as business highlights, at 4:30 p.m. Eastern Time the same day. A live we.

Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023

After decades of work and delay, Geron Corporation is finally approaching its first approval. That should be done by about H1 2024, and although the stock looks properly valued based on revenue projections, there are other factors in play. One of these is market enthusiasm, and if that is assumed, these prices are not going to return.

Geron Stock: These Prices Are Unlikely To Return

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an Expanded Access Protocol (EAP) is available for imetelstat, the Company's first-in-class telomerase inhibitor. As allowed under the U.S. Food and Drug Administration (FDA) policies, companies may offer an EAP, which permits an investigational medicinal product intended to treat a serious or life-threatening condition, such as lower risk myelodysplastic.

Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Denali Therapeutics

Recursion Pharmaceuticals

Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson's unique strategy to delay aging. This has investors trying to sniff out which biotech stocks to buy.

Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 72,770 shares of Geron common stock as inducements to a newly hired employee in connection with commencement of employment with the Company. The stock options were granted on June 21, 2023 at an exercise price of $3.22 per share, which is equal to the closing price of Geron common stock on the date of grant. Stock options representing.

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ES.

Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Company's first-in-class telomerase inhibitor, in patients with acute myeloid leukemia (AM)L, or higher risk myelodysplastic syndromes (MDS), who are relapsed/refractory/intolerant to hypomethylating agents (HMAs). “This trial is based on mul.

Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced new data and analyses from IMerge Phase 3 reporting robust durability of transfusion independence (TI), evidence for disease-modifying activity and favorable fatigue patient-reported outcomes (PRO) in lower risk myelodysplastic syndromes (MDS) patients treated with the Company's first-in-class telomerase inhibitor, imetelstat, vs. placebo. The data and analyse.

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, on Thursday, June 15, 2023 at 8:40 a.m. PT. A webcast of the presentation will be available through the Investor Relations section of Geron's website.

Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time. Topics to be covered at the event include: Summary of new IMerge Phase 3 data in lower risk myelodysplastic syndromes (MDS) featured in 2023 medical meetings. This includes presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023 and upcomin.

Geron to Host Virtual Investor Event on June 14, 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, announced a presentation reporting durable continuous transfusion independence with imetelstat, the Company's first-in-class telomerase inhibitor, in IMerge Phase 3 lower risk MDS patients. These data were presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. “The presentation at ASCO of our IMerge Phase 3 data highlighted the mean.

Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients

Geron Corporation (GERN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GERN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Geron (GERN) Just Flashed Golden Cross Signal: Do You Buy?

Geron Corporation's imetelstat has shown a clear benefit in treating lower-risk myelodysplastic syndromes (LR-MDS), with positive results in its phase 3 IMerge study. Imetelstat is likely to receive FDA approval for LR-MDS, with a potential priority review and a possible launch in H1 2024. Geron faces competition from Bristol-Myers Squibb's Reblozyl, but imetelstat's efficacy in heavily transfusion-dependent patients may provide differentiation from its competitors.

Geron: Ready To Face The Competition With Imetelstat In Lower Risk Myelodysplastic Syndromes

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced acceptance of its IMerge Phase 3 abstract as an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. This abstract describes statistically significant positive efficacy and safety data from the pivotal IMerge Phase 3 clinical trial evaluating the Company's first-in-class telomerase inhibitor, imetelstat, in lower.

Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Faraday Future Intelligent Electric

Tivic Health Systems

Use these tips to analyze sectors to find penny stocks to buy The post Sector Analysis With Penny Stocks: 3 Top Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Sector Analysis With Penny Stocks: 3 Top Tips

Nokia

Southwestern Energy

Debunking the most popular myths about penny stocks The post Top Myths About Penny Stocks Debunked appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Myths About Penny Stocks Debunked

Geron Corporation (NASDAQ:GERN ) Q1 2023 Results Conference Call May 11, 2023 10:30 AM ET Company Participants Aron Feingold - VP, IR and Corporate Communications Dr. John Scarlett - Chairman and CEO Olivia Bloom - EVP and CFO Dr. Faye Feller - EVP and CMO Anil Kapur - EVP, Corporate Strategy and Chief Commercial Officer Conference Call Participants Stephen Willey - Stifel Kalpit Patel - B. Riley Joel Beatty - Baird Gil Blum - Needham & Company Corinne Jenkins - Goldman Sachs Operator Good morning.

Geron Corporation (GERN) Q1 2023 Earnings Call Transcript

Geron (GERN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago.

Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted at the European Hematology Association (EHA) Annual Meeting taking place from June 8-11, 2023 in Frankfurt, Germany and virtually. The three EHA abstracts on IMerge Phase 3 data expand upon and further confirm the differentiating qualities of imetelstat that ca.

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates and financial results for the first quarter of 2023. “We believe that imetelstat has a compelling commercial value proposition and is well-positioned to become a standard of care in lower risk MDS, based on unprecedented broad durability of transfusi.

News for Geron Stock (GERN)